Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Fluicell AB (publ) is a Swedish life science company specializing in advanced single-cell technologies and tissue therapeutics. Established with a vision to push scientific boundaries, Fluicell develops high-precision platforms that enable detailed study of individual cells in their native environments, facilitating breakthroughs in biological research. The company’s flagship technology includes a microfluidic bioprinting system and the Nexocyte tissue engineering platform, which together support innovative applications in regenerative medicine and drug development. Fluicell focuses on creating tissue-based solutions targeting serious diseases such as type 1 diabetes, cardiac toxicity, and kidney disease. By providing cutting-edge research tools and pioneering tissue therapeutics, Fluicell plays a significant role in transforming disease treatment and advancing biomedical science at the cellular level.
kr 2.95
kr 0.27 (-8.39%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-139.87% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 222.9% YoY with margins expanding 712.3pp.
Negative free cash flow of -kr 14M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 12M
▲ +222.9% YoY
Net Income (TTM)
-kr 2M
▲ +46.3% YoY
Op. Margin
-20.72%
▲ +712.3pp YoY
ROIC
-44.02%
▲ +83.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 8M
▲ +29.0% YoY
Op. Cash Flow (TTM)
-kr 2M
▲ +63.2% YoY
Net Debt
-kr 2M
Net Cash Position
Cash & Equiv.
kr 2M
3Y CAGR: +22.7%
Continue Research
Fluicell AB (publ) (FLUI.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Fluicell AB (publ) scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Fluicell AB (publ) scores 50 out of 100 on Intrinsiqq's quality score, passing 4 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -20.7% operating margin and a -44.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh FLUI.XSTO's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.